Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRC 317: DS-Cav1 RSV Vaccine Phase I
NCT03049488Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2017
- Primary completion
- Oct 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DS-Cav1 in respiratory syncytial virus infection (RSV) (6 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms at 7 days, Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms at 7 days and 3 more. Started Feb 2017; status: completed.
02
Drugs
DS-Cav1
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03049488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03049488.